QUESTIONS ASKED: Are there financial ramifications associated with the paradigm shift of cancer care delivery away from community-based clinics (CCs) and toward hospital-based oncology clinics (HCs)? Furthermore, are any cost differences also accompanied by care quality differentials as measured by hospitalizations or emergency department (ED) visits?
Rates of hospitalization 72 hours and 10 days after chemotherapy were similar for patients in both cohorts (CC v HC at 72 hours: 2.3% v 2.2% [P = .6626]; at 10 days: 7.0% v 7.3% [P = .6198]). However, patients treated in the CC cohort had a 29% reduced risk of ED visits compared with the HC cohort (hazard ratio, 0.71; 95% CI, 0.54 to 0.95; P = .02).
WHAT WE DID: Cost data for patients with breast, lung, or colorectal cancer were extracted from the IMS LifeLink database. To control for clinical/demographic disparities between community and hospital patients, patients treated in the community setting were matched with those treated in a hospital-based clinic (2 to 1) on the basis of cancer type (breast v colon v lung cancer), specific chemotherapy received, receipt of radiation, metastatic disease, sex, prior surgery, and geographic region. Chemotherapy-specific costs included the cost of chemotherapy plus costs incurred on the same day of administration. Pharmacy costs included all costs associated with dispensation of outpatient prescriptions under the patients' prescription drug plans. Costs were standardized to 2015 US dollars ($) and analyzed PPPM. Hospitalizations, ED visits, physician visits, and other outpatient visits that occurred during follow-up were captured.
BIAS, CONFOUNDING FACTOR(S), DRAWBACKS:
Although this analysis included a subset of patients age 65 years or older, it did not include evaluation of patients with Medicare or Medicaid as their sole payer. As such, results are not generalizable to these populations.
REAL-LIFE IMPLICATIONS:
Treatment in the community practice is associated with lower total cost of treatment compared with hospital-based outpatient practices for patients with breast, lung, or colorectal cancer. An additional notable observation was the difference in ED visits after chemotherapy: those treated in the CC setting experienced fewer ED visits than those treated in the HC setting. These data provide real-world insight that calls for examination of reimbursement differentials across sites of care to ensure that access to high-quality cancer care is not diminished by limiting site of care options.
INTRODUCTION
Access to affordable, high-quality cancer care is essential for optimal outcomes, yet it remains a great challenge for patients with cancer.
1,2 Numerous factors may contribute to barriers for accessing high-quality cancer care, including uneven geographic distribution of oncology centers, health insurance, and increasing treatment costs. 1 Notably, annual cancer care costs are estimated to surpass $170 billion by 2020. 3 An emerging reason for geographic barriers and escalating costs is the shift of care delivery from community-based to hospital-based oncology practices. Since 2008, communitybased practice clinic closures have increased 121%, and acquisition of community practices by hospitals has increased by 172%. 4 This hospital acquisition of community-based practices has greatly increased the overall volume of hospital-based chemotherapy claims. 5, 6 This trend is particularly relevant to the cost of cancer care. Several analyses have sited a large cost differential between chemotherapy administered in community-and hospital-based outpatient clinics. [6] [7] [8] Given this shift in site-of-care provision, we evaluated the cost differences of cancer care provided to patients with breast, lung, or colorectal cancer treated in a community-based or a hospital-based outpatient clinic to better elucidate the potential financial implications of this trend. A matched-cohort approach was used to control for potential confounding factors while costs were compared for clinically and demographically similar patients treated with the same chemotherapy regimens.
METHODS

Data Source
A 10% random sample of medical and pharmacy claims was obtained from the IMS LifeLink database (Data Supplement). The data source is fully compliant with the Health Insurance Portability and Accountability Act.
Sample Selection
Included patients had at least one medical chemotherapy claim with a diagnosis of breast, lung, or colorectal cancer between July 1, 2010, and June 30, 2015. Patients were grouped into a community-clinic cohort (ie, CC cohort) or hospital-based outpatient-clinic cohort (HC cohort) according to the placeof-service codes and billing category for chemotherapy; patients must have received all chemotherapy in either the CC or HC setting and had continuous eligibility for 6 months in the pre-index period through end of follow-up. Patients with evidence of administration in both HC and CC settings were excluded. The first chemotherapydate was each patient's index date. Patients were observed for up to 1 year after the index date or until the first-line chemotherapy regimen was discontinued (defined as a 60-day period with no record of chemotherapy administration), whichever occurred first. All chemotherapy agents given within the 28-day post-index period were considered part of the first-line chemotherapy regimen. Regimens were categorized as branded plus generic agent(s), branded agent(s) only, and generic agent(s) only; the cost for each category was calculated separately from overall chemotherapy cost. Costs during first-line chemotherapy were defined as the amount paid for all services rendered during the patient's follow-up time. Total medical costs included all costs except those covered under pharmacy costs. Within total medical costs, chemotherapy-specific costs were defined as the cost paid for chemotherapy plus any costs incurred on the same day of chemotherapy administration. The cost of clinic-administered supportive care not given on the same day as chemotherapy administration was included in other outpatient costs. Pharmacy costs included all costs associated with dispensation of outpatient prescriptions under the patients' prescription drug plans; oral chemotherapy was included in the pharmacy costs. All costs were standardized to 2015 US dollars ($) and analyzed as cost per patient per month (PPPM). Hospitalizations, emergency department (ED) visits, and physician and other outpatient visits (defined as visits related to laboratory/ pathology work, radiology, or outpatient procedures [ie, surgical or diagnostic]) that occurred during follow-up were also captured. Chemotherapy-related ED visits and hospitalizations were defined as those that occurred within 72 hours and 10 days after chemotherapy to ensure that patients in both cohorts had equal opportunity to be evaluated by a provider within a defined timeframe before chemotherapy administration.
Statistical Analysis
To control for clinical and demographic disparities between cohorts, we matched patients treated in the community setting with those treated in a hospital-based clinic (2 to 1); patients were matched according to cancer type (breast v colon v lung cancer; matched patients had only one of these diagnoses throughout the study period), specific chemotherapy received, receipt of radiation therapy during follow-up, presence of metastatic disease (identified via diagnosis codes; Data Supplement), sex, prior surgery, and geographic region. Charlson comorbidity index (CCI) scores were computed to assess comorbidities between the cohorts; CCI was similar across both cohorts and was not included in the match. 9 Results were also stratified by age 65 years or older.
Categoric measures were presented as counts and percentages; means and standard deviations (SDs) were presented for continuous outcomes. The Wilcoxon signed rank sum test was conducted using SASversion 9.2 (SAS Institute; Cary, NC).
RESULTS
Atotalof 44,870 patientsdiagnosed and treatedforbreast, lung, or colorectal cancer were identified; of these, 7,467 patients met all inclusion criteria and 6,675 were matched 2 to 1 (community-based care [n = 4,450] v hospital-based care [n = 2,225]) according to characteristics previously described ( Fig  1) . Patient and disease-related characteristics for matched patients are listed in Table 1 ; patient and chemotherapy characteristics were similar before and after matching, which indicated that patients included in the matched cohort were not notably different from those excluded in observable characteristics. The mean CCI score was 4.7 (SD, 2.3) in the CC cohort and was 4.8 (SD, 2.4) in the HC cohort. Overall, 4,494 patients (67%) had breast cancer (metastatic disease in 50%), 1,428 (21%) had lung cancer (metastatic disease in 67%), and 753 (11%) had colorectal cancer (metastatic disease in 67%). There were no differences in baseline demographics when patients were separated according to cancer type (Data Supplement). For the Medicare-eligible stratification, 780 patients (17.5%) were in the CC cohort (17.5%), and 318 patients (14.3%) were in HC cohort; patient-and diseaserelated characteristics were also similar within this subset.
Treatment Patterns
Of the 4,494 matched patients who received chemotherapy for breast cancer (n = 2,996 in CC cohort; n = 1,498 in HC cohort), the most common regimens were cyclophosphamide plus doxorubicin (34%, each cohort), cyclophosphamide plus docetaxel (21%, each cohort), and trastuzumab, a platinum agent, and docetaxel (11%, each cohort). Overall, 17% received radiation therapy during follow-up (16%, CC cohort; 17%, HC cohort). The majority of patients with breast cancer received generic chemotherapy only (73%, each cohort) followed by combinations of branded and generic chemotherapy (17%, each cohort) and branded chemotherapy only (10%, each cohort). The mean duration of chemotherapy in each cohort was similar (CC cohort, 96.9 days [SD, 62.1 days], v HC cohort, 94.4 days [SD, 58.5 days]).
Of the 1,428 patients who received chemotherapy for lung cancer (n = 952 in CC cohort; n = 476 in HC cohort), the most common regimens were a platinum agent plus either etoposide (28%, each cohort), paclitaxel (26%, each cohort), or pemetrexed (25%, each cohort), and 37% in each cohort received radiation therapy during follow-up. Overall, 63% in each cohort received generic chemotherapy only, 33% received combinations of branded and generic chemotherapy, and 3% received branded chemotherapy only. The mean duration of chemotherapy for lung cancer in each cohort was similar (CC cohort, 95.5 days [SD, 48. Of the 753 patients who received chemotherapy for colorectal cancer (n = 502 in CC cohort; n = 251 in HC cohort), 61% received FOLFOX (oxaliplatin, fluorouracil, and leucovorin); this was combined with bevacizumab in 10% of patients in each cohort. Also, 19% in each cohort received single-agent fluorouracil, and 17% in each cohort received radiation therapy during follow-up. The majority of patients with colorectal cancer received generic chemotherapy only (67%, CC cohort; 74%, HC cohort) followed by branded chemotherapy only (17%, each cohort) and a combination of branded and generic chemotherapy (16%, CC cohort; 9%, HC cohort). The mean duration of chemotherapy in each cohort was similar (CC cohort, 123.7 days [SD, 69.5 days], v HC cohort, 115.9 days [SD, 64.4 days]).
Cost of Care
Across all tumor types, the mean total cost (ie, medical plus pharmacy costs) PPPM during the post-index period was $15,052 (SD, $13,321). The mean total cost PPPM was significantly lower in patients treated in a community-based practice compared with those treated in a hospital Results for patients who were eligible for Medicare were similar to the overall analysis: the CC cohort had significantly lower costs than the HC cohort; the mean total PPPM costs were $9,414 (SD, $13,171) in the CC cohort versus $14,440 (SD, $19,689) in the HC cohort (P = .0012). The cost differential observed in Medicare-eligible patients was, again, driven by lower PPPM medical costs ($9,078 [SD, $13,757] v $14,036 [SD, $19,721]; P = .0024).
Chemotherapy-Related Hospitalizations and ED Visits
Rates of hospitalization 72 hours and 10 days after chemotherapy across all patients were similar for patients treated in the community and hospital settings (CC v HC cohort: 72 hours after chemotherapy, 2.3% v 2.2% [P = .6626]; 10 days after chemotherapy, 7.0% v 7.3% [P = .6198]). However, rates of ED visits within 72 hours and within 10 days of chemotherapy administration were significantly lower in the CC cohort versus the HC cohort (CC v HC cohort: within 72 hours, 2.6% v 3.6% [P = .0055]; within 10 days, 7.9% v 9.8% [P = .0022]). This resulted in a risk reduction of 29% for ED visits for patients treated in the CC setting versus the HC setting (hazard ratio, 0.71; 95% CI, 0.54 to 0.95; P = .02). Furthermore, of the patients in the CC cohort who had at least one ED visit within 72 hours of chemotherapy administration (n = 114), a smaller proportion had multiple ED visits (ie, 2 or more) compared with patients who had at least one ED visit in the HC cohort (n = 80, HC; 7.9% v 16.3%, CC v HC). In addition to the lower rates of hospitalizations and ED visits in the CC versus HC cohort, patients in the CC cohort had a mean number of 4. significantly lower than for patients treated in the HC setting and that this difference is irrespective of treatment regimen, brand versus generic agents used, or tumor type. Overall, total mean PPPM costs were 59.9% higher in the HC setting than in the CC setting. This cost differential was driven largely by lower chemotherapy costs in community-based practices; this is despite the similarity in the number of cycles and the duration of therapy between the matched-cohort groups. This study supports previous findings, although the prior studies did not necessarily control for potential differences in patient or treatment characteristics. In a claims analysis of 283,502 patients who initiated treatment with infused chemotherapy, total reimbursement during the 6-month treatment episode was 48% lower when administered in physician offices rather than in hospital outpatient clinics ($ 8 In each study, the higher costs of cancer care in the hospital-based setting appear primarily driven by the increased cost of chemotherapy, not by disproportionate use of chemotherapy agents or chemotherapy sessions. 10 This is, again, consistent with our finding that the duration of therapy, overall and by cancer type, was similar within our two matched cohorts and therefore not contributory to the cost differential. This analysis expands on previous work by matching patients with specific tumor types; treatments; and other possible confounders, such as the presence of metastatic disease, surgery, radiation, and geographic region. Furthermore, upon the request of a peer review, an additional analysis of the data by propensity score matching as well as an evaluation of median cost were performed. The results of the propensity versus direct match and median (interquartile range) versus mean (SD) are available side by side (Data Supplement); these results did not change any conclusions. Stratification to those who were Medicare-eligible patients also showed similar results, although we did not specifically evaluate those with only Medicare as the payer. We anticipate, however, that the cost differential for this patient population would still show lower costs in the CC versus HC setting, because the increased cost of chemotherapy in the HC setting was not the only driver of increased medical costs. However, because Medicare pays the same amount for chemotherapy regardless of site of care, and because chemotherapy cost was a large contributor of the cost differential, the relative rate of increased cost for this population within the HC versus CC cohort may be less pronounced.
This cost differential demonstrated here, which was based on site-of-care delivery, is concerning, because emerging data have revealed a downward shift in access to community-based oncology care sites. 4 An earlier ASCO census report that focused on private community practices at risk noted that smaller practices reported the greatest risk of closure. 11 The underlying etiology that drives integration of smaller practices with larger health care systems is multifactorial and includes issues such as lower chemotherapy reimbursement, increasing regulatory compliance and facility costs, and payer pressure. 1, 11 Smaller practices may be more willing to integrate into larger systems because of complex changes in payment design, health record requirements, and electronic data exchange. 12 A recent survey of community oncology practices cited reimbursement rates for both drugs (98%) and chemotherapy (90%), as well as the cost of regulatory compliance (87%), as very important or extremely important challenges that threaten their ongoing viability. 4 As payers attempt to manage costs through narrowing networks, consolidation may be one way for both community-and hospital-based practices to increase their odds of being in network. 12 Regardless, this shift in site of cancer care provision is concerning as emerging data demonstrate higher costs of care in hospital-based versus community-based practices. In fact, consolidation may be a contributing factor itself in the increasing cost of cancer care as larger health care systems, via their market power, can negotiate higher prices from payers, which could lead to higher prices for patients. 12 A notable observation in our study was the difference in ED visits after chemotherapy administration, with rates of ED visits within 72 hours of 2.6% in the CC setting versus 3.6% in the HC setting (P = .0055); rates within 10 days were 7.9% in the CC setting and 9.8% in the HC setting. Also, a greater proportion of patients in the HC cohort had had multiple ED visits compared with patients in the CC cohort. This is particularly important, because a recent analysis of patients with advanced cancer concluded that 23% of ED visits were avoidable. 13 In addition, patients in the CC cohort had an increased PPPM number of other (ie, nonphysician) outpatient visits, which perhaps reveals a difference in resource use geared toward patient management in lower-cost outpatient sites that results in a lower need for ED visits. This is also important as we look toward alternative payment models, such as the one endorsed by the Centers for Medicare and Medicaid Services (ie, the Oncology Care Model), which specifically lists ED visits as a required reporting measure for practices to qualify for any performance-based reimbursement.
14 A limitation of this study is that, because the payer-type distribution within the data set is 80% commercial, we did not evaluate the cost differentials in the Medicare and Medicaid populations; therefore, results are not generalizable to these populations. In addition, despite a robust matching for anticipated confounding factors, other potential confounders, such as socioeconomic data, were not available for any patient. Finally, certain aspects of routine oncology care today (ie, genetic testing/counseling, survivorship care) cannot be evaluated using this type of data.
In conclusion, this study indicates that treatment in the community practice is associated with lower total cost of treatment and cost of chemotherapy when compared with hospital-based outpatient practices for patients with breast, lung, or colorectal cancer. These data provide real-world insight to payers, providers, policy makers, and other healthsystem stakeholders to examine reimbursement differentials across sites of care, such that patient access to high-quality cancer care is not diminished by limiting site of care options as a result of financial pressures. Because the timeframe of this data predated the widespread use of more expensive therapies, such as immune-checkpoint inhibitors, and because the results lack generalizability to the aging Medicare population as well as the Medicaid population, future research is needed.
